Literature DB >> 19592010

Rescuing macrophage function following severe thermal injury.

Jeremy L Herrmann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19592010      PMCID： PMC2787918          DOI： 10.1016/j.jss.2009.04.023

Source DB:  PubMed          Journal:  J Surg Res        ISSN： 0022-4804            Impact factor:   2.192


× No keyword cloud information.
  19 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 2.  Macrophage activation by immunostimulatory DNA.

Authors:  K J Stacey; D P Sester; M J Sweet; D A Hume
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

3.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.

Authors:  D M Klinman; A K Yi; S L Beaucage; J Conover; A M Krieg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

4.  Cyclooxygenase 2-mediated suppression of macrophage interleukin-12 production after thermal injury.

Authors:  Martin G Schwacha; Chun-Shiang Chung; Alfred Ayala; Kirby I Bland; Irshad H Chaudry
Journal:  Am J Physiol Cell Physiol       Date:  2002-02       Impact factor: 4.249

5.  Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma.

Authors:  Alexandre Carpentier; Florence Laigle-Donadey; Sarah Zohar; Laurent Capelle; Anthony Behin; Annick Tibi; Nadine Martin-Duverneuil; Marc Sanson; Lucette Lacomblez; Sophie Taillibert; Louis Puybasset; Remy Van Effenterre; Jean-Yves Delattre; Antoine F Carpentier
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

6.  Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock.

Authors:  Guillaume Monneret; Alain Lepape; Nicolas Voirin; Julien Bohé; Fabienne Venet; Anne-Lise Debard; Hélène Thizy; Jacques Bienvenu; François Gueyffier; Philippe Vanhems
Journal:  Intensive Care Med       Date:  2006-06-02       Impact factor: 17.440

7.  Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.

Authors:  John G McHutchison; Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Mitchell Shiffman; Nezam H Afdhal; Ira M Jacobson; Andrew Muir; Mohammed Al-Adhami; Mary L Morris; Julie A Lekstrom-Himes; Susan M Efler; Heather L Davis
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

8.  Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock.

Authors:  Fabienne Venet; Sylvie Tissot; Anne-Lise Debard; Caroline Faudot; Carine Crampé; Alexandre Pachot; Alfred Ayala; Guillaume Monneret
Journal:  Crit Care Med       Date:  2007-08       Impact factor: 7.598

9.  Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.

Authors:  John P Leonard; Brian K Link; Christos Emmanouilides; Stephanie A Gregory; Daniel Weisdorf; Jeffrey Andrey; John Hainsworth; Joseph A Sparano; Donald E Tsai; Sandra Horning; Arthur M Krieg; George J Weiner
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

10.  Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.

Authors:  Julien Fourcade; Pavol Kudela; Pedro A Andrade Filho; Bratislav Janjic; Stephanie R Land; Cindy Sander; Arthur Krieg; Albert Donnenberg; Hongmei Shen; John M Kirkwood; Hassane M Zarour
Journal:  J Immunother       Date:  2008-10       Impact factor: 4.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.